Abstract

6-(4-(4-Substituted phenylpiperazin-1-yl)butoxy)benzo[d][1,3]oxathiol-2-one Synthesis and biological evaluation as potential antipsychotic agents

Author(s): Radha Charan Dash, Sharad H. Bhosale and Kakasaheb R. Mahadik

A series of 6-(4-(4-substituted phenylpiperazin-1-yl)butoxy)benzo[d][1,3]oxathiol-2-one was synthesized. The anti-dopaminergic and anti-serotonergic activities of the synthesized compounds were evaluated as an approach to identify novel antipsychotic agent. 6-(4-(4- Substituted phenylpiperazin-1-yl)butoxy)benzo[d][1,3]oxathiol-2-ones were synthesized by reacting 6-(4-chlorobutoxy)benzo[d][1,3]oxathiol-2-one with substituted phenyl piperazines and were characterized by IR, 1H-NMR, C13-NMR, MS and elemental analysis. The antidopaminergic activity was evaluated by their ability to inhibit apomorphine induced climbing behavior and the anti-serotonergic activity of synthesized compounds was assessed by studying inhibition of 5-HTP induced head twitches in mice. The intensity of catalepsy induced by synthesised compounds was evaluated against haloperidol induced catalepsy. The pharmacological testing revealed that the compound 4l, 6-(4-(4-(2,3-dichlorophenyl)piperazin- 1-yl)butoxy)benzo[d][1,3]oxathiol-2-one and 4n 6-(4-(4-(2,3-dimethylphenyl)piperazin-1- yl)butoxy)benzo[d][1,3]oxathiol-2-one showed better antipsychotic profile with lower incidence of catalepsy induction.

PDF

30+ Million Readerbase

Google Scholar citation report

Citations : 25868

Der Pharma Chemica received 25868 citations as per Google Scholar report

Der Pharma Chemica peer review process verified at publons